Pregled bibliografske jedinice broj: 1174158
Adropin Serum Levels in Patients with Primary Sjögren’s Syndrome
Adropin Serum Levels in Patients with Primary Sjögren’s Syndrome // Biomolecules, 11 (2021), 9; 1296, 11 doi:10.3390/biom11091296 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1174158 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Adropin Serum Levels in Patients with Primary Sjögren’s Syndrome
Autori
Janković Danolić, Marijana ; Perković, Dijana ; Petrić, Marin ; Barišić, Igor ; Gugo, Katarina ; Božić, Joško
Izvornik
Biomolecules (2218-273X) 11
(2021), 9;
1296, 11
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
primary Sjögren’s syndrome ; adropin ; endothelial dysfunction ; anti SSA/Ro52 antibodies ; SSDDI
Sažetak
Primary Sjögren’s syndrome (pSS) patients have higher prevalence of endothelial dysfunction and premature atherosclerosis. Recent studies investigated adropin, a secretory protein that can regulate lipid metabolism and insulin resistance and protect endothelial cells’ function and that has an anti-inflammatory effect. The aim of this study was to determine adropin levels in pSS patients compared to healthy controls. Additional goals were exploring the correlation between adropin and several metabolic and immunological parameters in pSS, including disease specific antibodies, EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI), and Sjögren’s Syndrome Disease Damage Index (SSDDI). This research included 52 pSS patients and 52 healthy controls. pSS patients have significantly higher adropin levels compared to the control group (3.76 ± 0.68 vs. 3.14 ± 0.69 ng/mL, p < 0.001). Correlation analysis showed that adropin levels in pSS patients have positive correlation with high-density lipoprotein (HDL) (r = 0.290, p = 0.036) and anti SSA/Ro52 antibodies (r = 0.307, p = 0.026) and negative correlation with SSDDI (r = −0.401, p = 0.003). Multivariant linear regression showed that adropin levels are independently associated with HDL (β ± SE, 0.903 ± 0.283, p = 0.002) and SSDDI (β ± SE, −0.202 ± 0.073, p = 0.008). Our findings imply that adropin could be involved in the pathophysiology of pSS, yet it remains to be elucidated in future studies whether adropin has a protective or detrimental role in this setting.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
KBC Split,
Medicinski fakultet, Split
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE